NIH Forecasts a Parent R35 — One Award, One Lab, and an October 4, 2027 Due Date

NIH-funded principal investigators now have a date to plan against: on July 30, 2026, NIH posted a Grants.gov forecast for PAR-28-037, the Investigator-Focused Award (Parent R35), with an estimated application due date of October 4, 2027 and a projected July 1, 2028 start.

The forecast is thin on dollars and heavy on doctrine

The forecast record on Grants.gov contains no award ceiling, no award floor, no estimated program funding, and no anticipated number of awards. Those fields are all null. What it does contain is a statement of intent that is more consequential than any of the missing numbers.

NIH says it "intends to publish a Parent R35 'Investigator-Focused Award' Notice of Funding Opportunity (NOFO) to fund research programs for investigators at all career stages, including Early Stage Investigators (ESIs)." The award, per the forecast, "is intended to provide support for an investigator's program of research within the mission of the awarding Institute or Center (IC) rather than support for a pre-defined project with specific aims."

Then the sentence that should reorganize your five-year plan: "The R35 is typically expected to be an investigator's primary (or only) source of research funding from the awarding IC."

The listed benefits follow the standard R35 catechism — flexibility to follow the science as it evolves, stability to take on hard questions, time redirected from grant administration toward research, mentoring, and scientific service, and "a high potential for scientific breakthroughs by enabling investigators to think broadly." None of that is new language. What is new is that it now sits under a parent announcement number rather than an institute-specific PAR or RFA.

The administrative details matter more than they look. Cost sharing is not required. The funding instrument is a plain grant. The listed contact is not an institute program officer but the Office of Extramural Research, reachable at ParentR35@mail.nih.gov — a trans-NIH mailbox that did not exist before this posting. Estimated synopsis posting, meaning the date the actual NOFO text is expected to appear, is May 27, 2027. That gives applicants roughly four months and one week between the published rules and the estimated deadline.

Nine institutes signed on, and the absentee list is the real news

Forecast records carry CFDA (Assistance Listing) numbers, and PAR-28-037 carries sixteen of them. Decoded, they map to nine participating components: the National Cancer Institute (93.393 through 93.399, seven listings on its own), the National Eye Institute (93.543 and 93.867), NIGMS (93.859), NIEHS (93.113), NIDCR (93.121), NHGRI (93.172), NIMHD (93.307), the National Library of Medicine (93.879), and trans-NIH research support through the Office of the Director (93.310).

That is a real coalition, and it is also conspicuously partial. NHLBI, NINDS, NIAID, NIA, NIMH, NIDDK, NICHD, NIDA, NIAAA, NIAMS, NIBIB, NINR, NIDCD, NCCIH, NCATS, and Fogarty are not on the list as of the July 30 posting. Several of those institutes — NINDS and NHLBI most notably — already run their own R35-style program awards and have no obvious incentive to fold them into a parent. Others have never used the mechanism at all.

For a PI, this is the first triage question, and it is answerable today: does your awarding IC appear in that CFDA list? If you are funded primarily by NIAID or NIMH, the parent R35 as forecast does not currently reach you, and nothing about your FY2028 planning changes. If you are NCI-, NIGMS-, NEI-, or NIEHS-funded, it does. Participation lists on parent announcements move between forecast and publication in both directions, so this is a watch item, not a verdict.

Why a parent number changes the character of the mechanism

R35 is not a new activity code. NIGMS launched MIRA in 2015; NCI's Outstanding Investigator Award has been running since PAR-15-342. What has always constrained the mechanism is access. Each IC wrote its own announcement, set its own eligibility gates, and in some cases required institutional nomination rather than open application. NCI's OIA, for example, requires that candidates be nominated by their applicant organization and expects at least six calendar months of PD/PI effort, with substantial institutional commitment on top.

A parent announcement does the opposite of gating. It publishes one set of instructions, one submission path, and one review architecture across every participating IC, and it stays open across multiple receipt cycles. That is the same structural move NIH made when it cut its active funding opportunity count from more than 800 to fewer than 500 over the course of 2025 and 2026 — retiring narrow, topic-specific NOFOs and routing investigators toward broad, reusable parents. We covered that consolidation and what it did to investigator-initiated science in our analysis of the 800-NOFO drawdown.

The R35 parent is the logical endpoint of that logic applied to the investigator rather than the topic. Instead of NIH defining the science and the PI conforming, the PI defines a program and NIH funds the person for a long period. It is also, quietly, a budget-control instrument: one award per investigator per IC is administratively cheaper to manage than three concurrent R01s with three non-competing renewal cycles and three progress reports.

What the precedent awards suggest about the money

Since the forecast publishes no dollar figures, the honest answer is that nobody outside NIH knows the parent R35 budget cap yet. The existing R35s establish a range, and it is wide.

NIGMS MIRA sets Early Stage Investigator budgets at up to $250,000 in annual direct costs, holds new investigators generally at or below $275,000, and allows investigators with existing NIGMS research grants to request up to $750,000 in annual direct costs. NCI's Outstanding Investigator Award runs to $600,000 direct costs per year for seven years. So the plausible band for a parent R35 sits somewhere between $250,000 and $750,000 in annual direct costs, over a project period of five to seven years, with the specific number likely varying by IC even under a shared parent.

Run the arithmetic against your current portfolio before you get attached to the idea. A modular R01 at $250,000 direct costs per year is one unit. If you hold two R01s from the same IC and a supplement, a single R35 at $600,000 direct is roughly a wash on dollars while eliminating two renewal competitions — a good trade. If you hold three R01s across two ICs and a program project, the arithmetic is worse, and the "primary or only source of funding from the awarding IC" language becomes a constraint rather than a gift. That sentence is the one to litigate with your program officer.

Fourteen months is the planning window, not the writing window

The temptation with a fourteen-month horizon is to file it and revisit in a year. That inverts the actual work. The writing window here is short — an estimated May 27, 2027 NOFO release against an estimated October 4, 2027 due date leaves about eighteen weeks, and R35 applications are unusually hard to assemble on a deadline because they are not project proposals. They are arguments about a person's research program, its trajectory, and why the next five to seven years of it deserve to be funded as a unit.

An eighteen-week turn is not unusual for a federal science solicitation, and the pattern of who clears it is consistent. When USDA reopened the Research Facilities Act with $125 million for land-grant university infrastructure on a July 17 deadline, the institutions that submitted competitive packages were the ones already holding assembled documentation when the NOFO published. Compressed windows do not reward speed. They reward inventory.

What is long is the evidence window. R35 review weights productivity and program coherence over specific aims. Papers accepted in the next twelve months, trainees placed, resources shared, and the through-line connecting your last three grants are what a reviewer will read in fall 2027. Those are being produced now.

Three things are worth doing in the next quarter. Confirm your awarding IC is on the CFDA list and ask your program officer directly whether they intend to participate — the trans-NIH mailbox exists, and forecast-stage questions are exactly what it is for. Map your current and pending IC awards against a single-award future, including end dates, so you know whether an R35 would consolidate your portfolio or shrink it. And start writing the program narrative now, as a living document, rather than as a Q3 2027 sprint.

One caution worth stating plainly: this is a forecast, not a published NOFO. Forecast dates slip, participating ICs change, and NIH has withdrawn forecast opportunities before publication. Do not restructure a lab around an estimated date. Do position for it.

Next step: Search active NIH R35 and investigator-focused program awards on Granted to see which institute-specific R35s are open now — several are live while the parent works its way to publication, and an existing IC award is often the faster path than waiting fourteen months for PAR-28-037.

Sources: Grants.gov opportunity 363391 (PAR-28-037); NIH Office of Extramural Research forecast record, posted July 30, 2026; NIGMS MIRA (PAR-26-121); NCI Outstanding Investigator Award program materials.